Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134964 | 0.95 | — | — | |
| Ammonia Solution, Strong SCHEMBL6054701 | 0.91 | CA5A (0.42) | CA5ACA5BTSHRCA2CA1 | |
| SCHEMBL27903686 | 0.91 | CA5A (0.42) | CA5ACA5BTSHRCA2CA1 | |
| Water SCHEMBL28550873 | 0.91 | CA5A (0.42) | CA5ACA5BTSHRCA2CA1 | |
| SCHEMBL28446871 | 0.91 | CA5A (0.42) | CA5ACA5BTSHRCA2CA1 | |
| Phosphine SCHEMBL27502726 | 0.91 | CA5A (0.42) | CA5ACA5BTSHRCA2CA1 | |
| Ammonia Solution, Strong SCHEMBL27487772 | 0.91 | CA5A (0.42) | CA5ACA5BTSHRCA2CA1 | |
| Ethane SCHEMBL2590617 | 0.87 | CA5A (0.39) | CA5ACA5BTSHRCA2CA1 | |
| SCHEMBL5015875 | 0.84 | CA5A (0.36) | CA5ACA5BTSHRCA2CA1 | |
| SCHEMBL7213274 | 0.84 | CA5A (0.36) | CA5ACA5BTSHRCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070253942-A1 | Lectin-directed prodrug delivery system | ISIS INNOVATION LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20040171524-A1 | Lectin-directed prodrug delivery system | ISIS INNOVATION LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-1372734-A1 | LECTIN-DIRECTED PRODRUG DELIVERY SYSTEM | ISIS INNOVATION LIMITED (GB) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002080980-A1 | LECTIN-DIRECTED PRODRUG DELIVERY SYSTEM | ISIS INNOVATION LIMITED (GB) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171524-A1 | Lectin-directed prodrug delivery system | ENGASE, SIGLEC7, ST6GAL1 | CA5A 1350/4885CA5B 1428/4885TSHR 2597/4885 |
| US-20070253942-A1 | Lectin-directed prodrug delivery system | ENGASE, SIGLEC7, MASP2 | CA5A 1400/4885CA5B 1542/4885TSHR 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.